<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CDH17 &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cdh17/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 10 Oct 2026 23:54:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CDH17 &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Antibody-Drug Conjugate SCR-A008 Shows Powerful Tumor Suppression in Gastric Cancer Models</title>
		<link>https://bioengineer.org/new-antibody-drug-conjugate-scr-a008-shows-powerful-tumor-suppression-in-gastric-cancer-models/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 10 Oct 2026 23:54:51 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antibody-drug conjugate]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[CDH17]]></category>
		<category><![CDATA[gastric cancer]]></category>
		<category><![CDATA[Immunohistochemistry]]></category>
		<category><![CDATA[p-ERK]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[patient-derived xenograft]]></category>
		<category><![CDATA[Pharmacokinetics]]></category>
		<category><![CDATA[SCR-A008]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<category><![CDATA[tumor growth inhibition]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=413544</guid>

					<description><![CDATA[A novel CDH17-targeted antibody-drug conjugate called SCR-A008 achieved sustained tumor inhibition in gastric cancer PDX models, with a paclitaxel combination reaching 95 percent tumor growth inhibition.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">413544</post-id>	</item>
	</channel>
</rss>
